Sartorius Aktiengesellschaft

Healthcare · EUR · XETRA

SRTT212

Price

€187.8

+1.73%

Cap

€12.41B

Earnings

—

30d Trend

+11.4%

0NIQ

Loading chart data...

0 days · % change from startPowered by Brain47

Next earnings:2026-07-23

BRAIN47 SIGNAL

MODERATE

Risk Level63

Quality56

Momentum65

Technical52

Fundamentals38

Raw weighted: 50×Macro 0.99 (−1%)=50

RISK

63/100

90d Volatility

43.8%High

ATR %

3.9%High daily moves

Max Drawdown (1Y)

-20.2%Normal

QUALITY

56/100

ROE (avg)

10.4%Good

Piotroski F-Score

6/9Average

Debt/Equity

0.64Moderate

Margin Stability

CV 10.5%Stable

Accruals

2.9%Accrual heavy

Interest Coverage

3.4xAdequate

MOMENTUM

65/100

12-1M Momentum

+27.2%Strong uptrend

6-1M Momentum

-1.3%Flat

1M Return

+8.6%Strong recent gains

Relative Strength

-1.3% vs sectorIn-line

TECHNICAL

52/100

RSI (14)

56.3Neutral

Price vs SMA200

+4.6%Bullish trend

MACD

+0.02Bullish momentum

Bollinger Band

64%Mid-range

SMA Cross

Death CrossDeath Cross

Trend Quality (KER)

0.292Noisy/choppy

FUNDAMENTALS

38/100

EV/EBIT

39.9Expensive

P/S

2.4Fair

Macro: neutral (×0.99) - Fear/Greed: 65 (Greed) - Data: 100%

Running historical backtest...

BRAIN47 HORIZON ANALYSIS

<3 months57

3-12 months ★64

1-5+ years51

3-6 month opportunity — emerging trend

BRAIN47'S ASSESSMENT

I rate Sartorius Aktiengesellschaft at 50/100 — a MODERATE reading on the Brain47 Signal. The strongest factor is momentum at 65/100. I classify this as a growth position with the strongest thesis on a medium-term horizon.

DETAILED ANALYSIS

3-6 month opportunity — emerging trend. Momentum (65) and Quality (56) are the primary strengths. I note an elevated risk profile — this warrants closer monitoring. I classify this as a growth position — strong momentum combined with growth potential points to capital appreciation.

growthScore: 50/100

Want full analysis on every stock?

Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.

Join Brain47 — Free

Generated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.